Evidence map›Paper›PMID 37038190›Full record

ArticleAlzheimer's research & therapy2023

Plasma NfL is associated with the APOE ε4 allele, brain imaging measurements of neurodegeneration, and lower recall memory scores in cognitively unimpaired late-middle-aged and older adults.

Michael Malek-Ahmadi, Yi Su, Valentina Ghisays, Ji Luo, Vivek Devadas, Yinghua Chen, Wendy Lee, Hillary Protas, Kewei Chen, Henrik Zetterberg and 3 more

Open access · goldAbstract read
In one paragraph

Article in Alzheimer's research & therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
9.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 43 citations in OpenAlex.

  1. Observational
  2. Journal of Korean medical science · 2026
    Article
  3. Review
  4. APOE and plasma AD biomarkers: The role of genetic ancestry in Hispanics/Latinos.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Multifaceted roles of APOE in Alzheimer disease.Nature reviews. Neurology · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 3 countries.

Michael Malek-AhmadiBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA. michael.malekahmadi@bannerhealth.com.
Yi SuBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Valentina GhisaysBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Ji LuoBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Vivek DevadasBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Yinghua ChenBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Wendy LeeBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Hillary ProtasBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Kewei ChenBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Henrik ZetterbergDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Kaj BlennowDepartment of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Richard J CaselliMayo Clinic Arizona, Scottsdale, AZ, USA.
Eric M ReimanBanner Alzheimer's Institute, 901 E. Willetta St., Phoenix, AZ, 85006, USA.
Alzheimer's Association · USBanner Alzheimer’s InstituteMayo Clinic in Arizona · USNational Hospital for Neurology and Neurosurgery · GBUniversity of Arizona · USUniversity of Gothenburg · SE

Funding

SUPPLEMENT TO ALZHEIMERS DISEASE PATIENT REGISTRYU01AG006786 · NIA · MAYO CLINIC ROCHESTER · PI GRAFF-RADFORD, JONATHAN, JACK, CLIFFORD R. · 1986 to 2023
$49.6M
THE PGRN/TDP-43 AXIS IN ALZHEIMER?S DISEASE AND NEURODEGENERATIONP50AG016574 · NIA · MAYO CLINIC ROCHESTER · PI PETERSEN, RONALD C · 1999 to 2018
$36.9M
Research Education ComponentP30AG019610 · NIA · SUN HEALTH RESEARCH INSTITUTE · PI REIMAN, ERIC MICHAEL · 2001 to 2020
$32.5M
APOE in the Predisposition to, Protection from and Prevention of Alzheimer's DiseaseR01AG069453 · NIA · BANNER HEALTH · PI ASHTON, NICHOLAS, LANGBAUM, JESSICA BROOKE · 2020 to 2025
$27.4M
Research Education ComponentP30AG072980 · NIA · BANNER HEALTH · PI Nicholas Ashton · 2021 to 2026
$24.9M
PET, APOE & the Preclinical Course of Alzheimer's DiseaseR01AG031581 · NIA · BANNER ALZHEIMER'S INSTITUTE · PI CASELLI, RICHARD J., REIMAN, ERIC MICHAEL · 2008 to 2018
$16.6M
Disease pathways in the population determined by amyloid, tau, and neurodegeneration imaging biomarkersR37AG011378 · NIA · MAYO CLINIC ROCHESTER · PI CLIFFORD R. JACK · 2018 to 2026
$6.8M
Validating the New Criteria for Preclinical Alzheimer's diseaseR01AG041851 · NIA · MAYO CLINIC ROCHESTER · PI JACK, CLIFFORD R., KNOPMAN, DAVID S · 2012 to 2021
$6.3M
European Research Council 681712NIA NIH HHS P30 AG019610NIA NIH HHS P30 AG072980NIA NIH HHS P50 AG016574NIA NIH HHS R01 AG031581NIA NIH HHS R01 AG041851NIA NIH HHS R01 AG069453NIA NIH HHS R37 AG011378NIA NIH HHS U01 AG006786
6 · The paper itself

Abstract

backgroundPlasma neurofilament light (NfL) is an indicator of neurodegeneration and/or neuroaxonal injury in persons with Alzheimer's disease (AD) and a wide range of other neurological disorders. Here, we characterized and compared plasma NfL concentrations in cognitively unimpaired (CU) late-middle-aged and older adults with two, one, or no copies of the APOE ε4 allele, the major genetic risk factor for AD. We then assessed plasma NfL associations with brain imaging measurements of AD-related neurodegeneration (hippocampal atrophy and a hypometabolic convergence index [HCI]), brain imaging measurements of amyloid-β plaque burden, tau tangle burden and white matter hyperintensity volume (WMHV), and delayed and total recall memory scores.

methodsPlasma NfL concentrations were measured in 543 CU 69 ± 9 year-old participants in the Arizona APOE Cohort Study, including 66 APOE ε4 homozygotes (HM), 165 heterozygotes (HT), and 312 non-carriers (NC). Robust regression models were used to characterize plasma NfL associations with APOE ε4 allelic dose before and after adjustment for age, sex, and education. They were also used to characterize plasma NfL associations with MRI-based hippocampal volume and WMHV measurements, an FDG PET-based HCI, mean cortical PiB PET measurements of amyloid-β plaque burden and meta-region-of-interest (meta-ROI) flortaucipir PET measurements of tau tangle burden, and Auditory Verbal Learning Test (AVLT) Delayed and Total Recall Memory scores.

resultsAfter the adjustments noted above, plasma NfL levels were significantly greater in APOE ε4 homozygotes and heterozygotes than non-carriers and significantly associated with smaller hippocampal volumes (r =  - 0.43), greater tangle burden in the entorhinal cortex and inferior temporal lobes (r = 0.49, r = 0.52, respectively), and lower delayed (r =  - 0.27), and total (r =  - 0.27) recall memory scores (p < 0.001). NfL levels were not significantly associated with PET measurements of amyloid-β plaque or total tangle burden.

conclusionsPlasma NfL concentrations are associated with the APOE ε4 allele, brain imaging biomarkers of neurodegeneration, and less good recall memory in CU late-middle-aged and older adults, supporting its value as an indicator of neurodegeneration in the preclinical study of AD.

Indexed as

Alzheimer DiseaseApolipoprotein E4AgedAllelesAmyloid beta-PeptidesBrainCohort StudiesHumansMiddle AgedNeuroimagingPositron-Emission Tomographytau ProteinsAmyloid beta-PeptidesApolipoprotein E4tau Proteins

Identifiers

PMID37038190
PMCPMC10084600
OpenAlexW4363650739

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.